Several MedTech initiatives from Twente have been awarded REACT-EU funding. The millions in subsidies will give the relevant companies and researchers in Twente an enormous boost, demonstrate the potential of MedTech in the region and strengthen Kennispark Twente as a MedTech hotspot.
Green light for MedTech Factory
In the MedTech Factory, start-up and fast-growing companies in medical technology will soon have access to high-quality and affordable microbiology labs. They can rent flexible space at the MedTech Factory until they are large enough to have their own building. The concept can be realised by initiators Novel-T and Kennispark Twente with the 3.1 million EFRO subsidy and the contribution already allocated from the RegioDeal via TwenteBoard.
Together with its regional partners, Novel-T recently presented its ambition to give the MedTech cluster in Twente a solid boost in the coming years. In September 2020, Jaap Beernink (CEO of Novel-T) and Eddy van Hijum (member of the Provincial Executive of Overijssel) presented an investment agenda on behalf of the regional cluster to State Secretary Mona Keijzer. On this agenda, affordable lab facilities were high on the priority list.
Anne-Wil Lucas, Area Director of Kennispark: “This grant is fantastic news for the region and Kennispark Twente. Without these subsidies, such facilities would never get off the ground, while they are essential for the continued growth of companies. This will ensure that we can retain Twente’s MedTech companies and attract companies from outside Twente.”
Consortia of knowledge institutes and Twente MedTech companies
In addition to the MedTech Factory, the other REACT-EU awards include various consortia of Twente MedTech companies and the University of Twente. These are collaborations that aim to use medical technology to contribute to an improved and affordable healthcare sector. These projects demonstrate the innovative capacity and power of cooperation within the regional cluster.
Innovations for the treatment of dementia and improved detection of breast cancer
For example, over 1.5 million euros was awarded to the ‘reMIND’ initiative, in which Demcon, Micronit and Locsens are consortium partners. Within reMIND, the parties bring together four different technologies to better treat dementia.
A second consortium, consisting of PA Imaging, Hemabo and the University of Twente in collaboration with Radboud UMC, will receive up to EUR 2.6 million for bringing photo-acoustic mammography to the patient.
A third example is the consortium formed around LioniX International, which includes Bronkhorst High-Tech, SurfiX, Qurin Diagnostics and PHIX. Together they are working on the SensorChip aimed at developing various types of gas, liquid and biosensors. They will receive over EUR 2.5 million for this project.
Finally, the Enschede-based company ILT Fineworks is involved in the industrialisation of the ELENA Heart Technology, for which a maximum of 1.7 million euros has been granted.
Jaap Beernink, CEO of Novel-T: “The award of these REACT-EU grants for both specific innovation projects and for strengthening the facilities in the ecosystem are of great importance for the development of the rapidly growing MedTech cluster in Twente. Innovative growth companies are the driving force behind this. For the region, the impact of these companies is particularly large, both from a social and economic perspective.”
About MedTechTwente
MedTech Twente is the innovation hub where medical technology is accelerating. For the past 15 years, the business community and healthcare institutions have been working closely together with researchers from the knowledge institutions to develop innovations for tomorrow’s healthcare. Innovations are developed, validated and implemented in close cooperation between parties, facilitated and accelerated by supporting organisations such as Novel-T, OostNL, VitaalTwente, HIP, WTC and HealthValley. It is therefore not without reason that successful MedTech companies such as Demcon, Medspray, Micronit, Lipocoat and IAMFluidics were founded and have grown in Twente.
About REACT-EU
The European Union is working with its recovery programme EU Next Generation on a fast, green, digital and resilient recovery of the regional economy. Under the name REACT-EU, 47.5 million euros – of which 5.9 million euros government co-financing – has been made available for the East Netherlands in 2021. This amount will be awarded to projects that have successfully submitted an application by 1 April. These projects must be completed by the end of 2023 so that the regional economy can recover as quickly as possible. The extra money has therefore been made available through the existing EFRO programme OP East 2014-2020. In OP Oost, the provinces of Gelderland and Overijssel work together to stimulate smart, sustainable and future-oriented projects at companies in the East Netherlands.
Source news: Kennispark Twente
Join the iMNC21 business floor for networking and a company pitch
As we are returning from summer holidays and planning for the second half of 2021, the iMNC21 team looks forward to greet more exhibitors who will present on December 2 and 3, 2021 in Utrecht.
The scientific program has a nice balance between speakers from industry and science on various topic ranging from Nano4Health in diagnostics, Nano4AgriFood to miniaturization and manufacturing in nanotechnology amongst the themes.
Business floor opportunities
Next to the keynote and invited speakers in the conference program, themes, there is room for networking and discussion on the business floor where participants can check demonstrations and meet with technical teams from the sponsors over a cup of coffee.
A pitch session for exhibitors will give all attendees a quick overview of who is presenting at iMNC21 and will make it easier to find the right connection for your next project.
Startup corner
At the iMNC21 we welcome startup companies who will receive a discount price, to make sure that all companies have the opportunity to present at iMNC21. Join Alex Kostenko from Photosynthetic, the Pitch Award winner of the iMNC2020 at the conference this year.
iMNC21 exhibitor benefits
As an exhibitor, you will also have a prominent place on the iMNC21 event website and in the matchmaking program from B2Match. Visibility and expanding your network are important goals that we help our exhibitors to achieve in the months leading up to the conference and at the event.
Will your company join companies like JEOL, Lionix International, MASER Engineering and Bronkhorst at the conference in December? Sign up for your booth today, to make sure you have a spot.
Read more about the exhibitor opportunities here or download the sponsor brochure direct (pdf).
QuiX delivers its processor to Germany!
QuiX Quantum, the worldwide market leader in quantum photonic processors, has delivered a 12-mode quantum photonic processor to Germany, for a collaboration with researchers from Paderborn University. This photonic processor is the most powerful in the world.
Quantum photonic processors are the central component of photonic quantum computers, holding great promises in performing certain computations faster than current supercomputers. Machine learning, chemistry and finance are believed to be revolutionized by such quantum technology.
QuiX Quantum lead engineer Caterina Taballione says: “This collaboration confirms the continuing interest in our products from the major players in the international quantum photonics landscape. Paderborn University is at the forefront of integrated optics, and we look forward to the results of this collaboration.”
The announcement comes on the heels of the announcement of a sale to Qontrol, a British quantum technologies startup, and a sale to Quandela, the leading French quantum technologies firm. Prof Christine Silberhorn, head of the Integrated Quantum Optics group and spokeswoman of the Institute for Photonic Quantum Systems (PhoQS), says: “We have chosen QuiX because of the high quality, turnkey linear optical circuit as used for demonstrating quantum advantage in boson sampling experiments, that only QuiX can deliver.”
QUIX | Forward.one – Vrijdag 22 januari 2021 | © Verkijk
Germany has recently published its ‘Roadmap Quantencomputing’, which sketches the required steps on the way towards a working quantum computer. As a result, the German government announced a 2 billion Euro funding initiative for the development of quantum technologies in general and quantum computers in particular.
The success that QuiX Quantum’ products are having highlights the dominant position of photonics in the quantum computing landscape in the Netherlands, being the only able to provide turn-key quantum solutions.
Quantum Delta NL launches two million euro micro fund for quantum startups
From left to right: Ton van ‘t Noordende (Investor in Residence, Quantum Delta NL), Matthijs Rijlaarsdam (QuantWare). Alessandro Bruno (QuantWare), Freeke Heijman (director Quantum Delta NL). Photos by Rebekka Mell, in the DiCarlo Lab (QuTech).
Quantum Delta NL announces the launch of a two million euro micro fund called ‘LightSpeed Fund 1’. The fund will focus on supporting early stage quantum startups. Delft-based startup and participant in the LightSpeed program, QuantWare, is the first startup to receive funding.
The fund is part of Quantum Delta NL’s strategic roadmap to increase the number of successful quantum startups in the Netherlands. Currently, there are seven quantum startups in the Netherlands, and Quantum Delta NL is on a mission to see this number increase to 100 by 2027. These companies are considered to become of great value to the Dutch economy.
In pursuit of this goal, last month Quantum Delta NL launched its new initiative, LightSpeed. Lightspeed is a program connecting Dutch quantum startups in all phases, where the startups receive tailored assistance and guidance to scale up their businesses and optimize their attractiveness to top-tier investors. Specifically for the initiative, efforts were made to approach and bring in European and American funds with a wealth of experience to support startups. Lightspeed aims to create optimal conditions to build sustainable and future-proof startups.
Fund
Following today’s launch of the micro fund, managed by LightSpeed, Quantum Delta NL awards pre-seed tickets amounting to 50,000 euros each to early-stage startups in the field of quantum technology. LightSpeed adapted a modern instrument that is straightforward, founder-friendly and fills the gap in the earliest stage for quantum technology startups: the SAFE note (Simple Agreement for Future Equity). This approach gives startups the maximum flexibility needed in the earliest stages, particularly in the quantum technology space as development timelines and road to profitability extend far beyond that of classic startups. The investment does not have to be repaid, as with a traditional convertible loan or note, if a startup fails to advance.
Quantum Delta NL’s Investor in Residence Ton van ‘t Noordende clarifies: “The Netherlands has a top position globally if we look at the number of quantum technology startups. This is unfortunately not the case on the capital side as there is virtually no professional venture capital available for early stage quantum startups. Our goal with Lightspeed is to enable founders to get the best possible start of their company.”
Quantum Delta NL has currently allocated two million euros for the pre-seed tickets and intends to award 5 to 15 tickets in fiscal year 2021/2022 and 35 to 40 tickets over the total period. The budget will be increased once Phase 1 of the National Growth Fund Program is underway.
QuantWare
QuantWare, a spinout of QuTech and part of the Quantum Delft ecosystem which develops high-performance quantum processors, is the first startup to tap into the microfund as part of a larger investment round. This makes it the second success story in the LightSpeed program. LightSpeed has also supported and guided the Delft-based startup QphoX in their fundraising round, which raised two million euros in funding with the help of the LightSpeed team to bring its Quantum Modem to the market.
Ambition
Startups and building a business ecosystem are key pillars of the Quantum Delta NL-program that heard it will receive 615 million euros from the National Growth Fund in April. Among other things, the program fuels the further development of the first European quantum computer and a quantum internet, openly accessible to end users in business and social sectors, including education. McKinsey calculated that in the medium term, the program will raise the gross domestic product by 5 to 7 billion euros and create 30,000 high-quality jobs in the Netherlands.
Freeke Heijman, director Quantum Delta NL: “We want the knowledge from the scientific labs to lead to new businesses in the Netherlands and Europe. With LightSpeed and this fund, promising initiatives will get an unprecedented acceleration to scale up their idea to a startup or scale-up.”
Ton van ‘t Noordende, Investor in Residence Quantum Delta NL: “We see the micro fund as a logical extension of LightSpeed. Promising and early stage initiatives only need a small injection of capital to hit the ground running. This is proven by QuantWare which, relying on our investment and on Lightspeed’s guidance, has raised immediate market capital even before launching their company.”
Alessandro Bruno, Director of Engineering at QuantWare: “The support from this fund and LightSpeed will allow us to bring our quantum processors to market. In doing so, we are making quantum accessible to more parties. In this way, we can make a crucial contribution that allows the Dutch quantum ecosystem to build on its current lead.”
Original press release here
QuiX’ photonic processor is published!
22 July 2021 – QuiX Quantum reports the realization of the largest Universal Quantum Photonic Processor in a scientific paper published today.
In a scientific paper published in Materials for Quantum Technology today, QuiX Quantum demonstrates the world’s largest universal quantum photonic processor, which shows excellent performance for quantum information processing and computing applications. With this work, QuiX Quantum demonstrates the first commercially available, turn-key processor for photonic quantum computing.
The results reported in the paper highlight the unique expertise of QuiX Quantum in combining photonic and quantum systems engineering, and the market-readiness of the technological solution. QuiX’ expertise and technology can provide solutions for the entire spectrum of quantum applications.
Photonic processors are a crucial component for photonic quantum computing, which promise great impact in the fields of machine learning, quantum chemistry and cryptography. The universal quantum photonic processor reported in the paper is embedded in a plug-and-play control system operated by QuiX’ dedicated control software.
QuiX Quantum’s CTO Jelmer Renema says: “With this work we have demonstrated not only a leading position in the commercial landscape of photonics quantum computing, but also in the technological development of quantum photonic engineering.”
QuiX Quantum is a company based in Enschede, the Netherlands, that realizes quantum technology solutions based on the proprietary silicon nitride waveguide technology TriPleX that enables the realization of large-scale integrated photonic circuits with low loss. The maturity of the waveguide technology allows for achieving full reconfigurability and all-to-all connectivity of the elements of the photonic processor that can be thus defined as universal.
Photo credit: Daniël Verkijk
Source: Quix News
First exhibitors for iMNC21 announced: Bronkhorst, Lionix, Maser and PhotoSynthetic
The first MinacNed members have registered as an exhibitor for the international MicroNanoConference 2021 on December 2-3, 2021.
iMNC21 theme
From science to market – scale-up in nanotech
First sponsors include Bronkhorst High-Tech, a leading company in the field low flow fluidics handling technology. Also Lionix International BV, a leading global provider of customized microsystem solutions in scalable production volumes. And earlier we announced Maser Engineering BV, an independent engineering service company that offers Reliability Test and Failure Analysis Services to the semiconductor and electronic systems industry.
Also this year a start-up corner with PhotoSynthetic, with CEO Alexander Kostenko who won the Best Company PItch Award at the online iMNC2020. and part of the start-up corner is PhotoSynthetic. Photosynthetic is developing a 3D lithography technology allowing to 3D print objects with feature sizes of less than a micron and print speeds of 1-10mm3 / minute.
Are you considering to join the iMNC21 as an exhibitor, then here is what the International MicroNanoConference 2021 offers you:
Read more about exhibitor opportunties and download the flyer at www.micronanoconference.org/exhibitor-info-imnc21/
Read more about MinacNed members and sponsors:
Bronkhorst High-Tech
Lionix International BV
Maser Engineering BV
PhotoSynthetic
Next step for NXTGEN HIGHTECH ‘Groeifonds’ Proposal
The ‘Groeifonds’ proposal NXTGEN HIGHTECH is selected to be worked out in detail to be submitted in October 2021. The Netherlands is an international leader when it comes to ultra-precision high-tech equipment and aims to exploit this expertise in NXTGEN HIGHTECH for production of Organs-on-Chips, among others. In total, 28 projects were selected from 244 initial submissions.
The ‘Topsector HTSM’ has, in close collaboration with knowledge institutes, governments, industry and other topsectors, initiated this widely supported programme (budget € ~1.5 billion) to develop the next generation High Tech Equipment for these industries. One of the six domains of NXTGEN HIGHTECH is ‘Biomedical Production Technologies’ and is being coordinated by Berend van Meer on behalf of hDMT. This domain aims at large scale production of Labs-on-Chips, Organs-on-Chips, Artificial Organs and Cell Production Equipment, in which industrial standardisation and qualification are indispensable.
In case the project will be funded, hDMT partners will be involved closely in the further elaboration and setup of the next steps. For more information about NXTGEN HIGHTECH see https://www.hollandhightech.nl/nxtgen-hightech and about the National ‘Groeifonds’ see https://www.nationaalgroeifonds.nl/.
Source: hDMT
Over 11 million React-EU funds awarded to Kennispark companies and Twente Medtech cluster
Several MedTech initiatives from Twente have been awarded REACT-EU funding. The millions in subsidies will give the relevant companies and researchers in Twente an enormous boost, demonstrate the potential of MedTech in the region and strengthen Kennispark Twente as a MedTech hotspot.
Green light for MedTech Factory
In the MedTech Factory, start-up and fast-growing companies in medical technology will soon have access to high-quality and affordable microbiology labs. They can rent flexible space at the MedTech Factory until they are large enough to have their own building. The concept can be realised by initiators Novel-T and Kennispark Twente with the 3.1 million EFRO subsidy and the contribution already allocated from the RegioDeal via TwenteBoard.
Together with its regional partners, Novel-T recently presented its ambition to give the MedTech cluster in Twente a solid boost in the coming years. In September 2020, Jaap Beernink (CEO of Novel-T) and Eddy van Hijum (member of the Provincial Executive of Overijssel) presented an investment agenda on behalf of the regional cluster to State Secretary Mona Keijzer. On this agenda, affordable lab facilities were high on the priority list.
Anne-Wil Lucas, Area Director of Kennispark: “This grant is fantastic news for the region and Kennispark Twente. Without these subsidies, such facilities would never get off the ground, while they are essential for the continued growth of companies. This will ensure that we can retain Twente’s MedTech companies and attract companies from outside Twente.”
Consortia of knowledge institutes and Twente MedTech companies
In addition to the MedTech Factory, the other REACT-EU awards include various consortia of Twente MedTech companies and the University of Twente. These are collaborations that aim to use medical technology to contribute to an improved and affordable healthcare sector. These projects demonstrate the innovative capacity and power of cooperation within the regional cluster.
Innovations for the treatment of dementia and improved detection of breast cancer
For example, over 1.5 million euros was awarded to the ‘reMIND’ initiative, in which Demcon, Micronit and Locsens are consortium partners. Within reMIND, the parties bring together four different technologies to better treat dementia.
A second consortium, consisting of PA Imaging, Hemabo and the University of Twente in collaboration with Radboud UMC, will receive up to EUR 2.6 million for bringing photo-acoustic mammography to the patient.
A third example is the consortium formed around LioniX International, which includes Bronkhorst High-Tech, SurfiX, Qurin Diagnostics and PHIX. Together they are working on the SensorChip aimed at developing various types of gas, liquid and biosensors. They will receive over EUR 2.5 million for this project.
Finally, the Enschede-based company ILT Fineworks is involved in the industrialisation of the ELENA Heart Technology, for which a maximum of 1.7 million euros has been granted.
Jaap Beernink, CEO of Novel-T: “The award of these REACT-EU grants for both specific innovation projects and for strengthening the facilities in the ecosystem are of great importance for the development of the rapidly growing MedTech cluster in Twente. Innovative growth companies are the driving force behind this. For the region, the impact of these companies is particularly large, both from a social and economic perspective.”
About MedTechTwente
MedTech Twente is the innovation hub where medical technology is accelerating. For the past 15 years, the business community and healthcare institutions have been working closely together with researchers from the knowledge institutions to develop innovations for tomorrow’s healthcare. Innovations are developed, validated and implemented in close cooperation between parties, facilitated and accelerated by supporting organisations such as Novel-T, OostNL, VitaalTwente, HIP, WTC and HealthValley. It is therefore not without reason that successful MedTech companies such as Demcon, Medspray, Micronit, Lipocoat and IAMFluidics were founded and have grown in Twente.
About REACT-EU
The European Union is working with its recovery programme EU Next Generation on a fast, green, digital and resilient recovery of the regional economy. Under the name REACT-EU, 47.5 million euros – of which 5.9 million euros government co-financing – has been made available for the East Netherlands in 2021. This amount will be awarded to projects that have successfully submitted an application by 1 April. These projects must be completed by the end of 2023 so that the regional economy can recover as quickly as possible. The extra money has therefore been made available through the existing EFRO programme OP East 2014-2020. In OP Oost, the provinces of Gelderland and Overijssel work together to stimulate smart, sustainable and future-oriented projects at companies in the East Netherlands.
Source news: Kennispark Twente
Parker Labs Leads Investment in Solstice Pharma’s Innovative Ultrasound Contrast Agent
ENSCHEDE, Netherlands & FAIRFIELD, New Jersey, USA, 2nd July 2021 — Solstice Pharmaceuticals has successfully completed its latest round of funding to further the clinical development of its innovative ultrasound contrast agent (UCA). The first-of-its-kind contrast agent uses unique microbubble technology that dramatically enhances image contrast, improves diagnostic accuracy and makes ultrasound more widely applicable for a wide range of diagnostic and therapeutic applications.
The investment comes from a consortium of experienced entrepreneurs and strategic industry partners, led by U.S.-based Parker Laboratories, a worldwide leader in ultrasound products for more than 60 years. The funding marks an important strategic step for Solstice that will enable the company to accelerate clinical translation of the proprietary UCA by demonstrating both patient safety and product versatility.
“This is a unique opportunity for Solstice both in terms of international growth and transitioning to the clinical market,” said managing director Wim van Hoeve. “We look forward to working with an experienced and diverse group of shareholders to accelerate our innovation and boost our international collaborations to establish new and exciting therapeutic and diagnostic applications.”
Unique Microbubble Technology
A key pillar of Solstice’s innovation is its lab-on-a-chip production technology, which enables the contrast agent to be precisely engineered and optimized with tailor-made monodisperse microbubbles for a broad range of specific applications. The novel microfluidic technology provides up to 20 times greater image contrast compared to existing UCAs. This improves the diagnostic accuracy of ultrasound, making it a fast, cost-effective and patient-friendly imaging technique to visualize the structures and details of a patient’s organs.
“We regard the ultrasound imaging market as a primary business segment and an important global growth area,” said Neal Buchalter, president of Parker Laboratories. “The unique technology platform of Solstice can play a pivotal role in increasing the versatility and applicability of ultrasound even further, which was a key factor for our investment in this promising start-up.”
Solstice plans to pursue the diagnosis of renal cell carcinoma (RCC) as the first clinical indication. RCC is the most common type of kidney tumor diagnosed in adults, but one-third of patients are diagnosed too late, after the cancer has already spread to other areas of the body. CT and MRI contrast agents are damaging to the kidneys and therefore contraindicated for diagnosing renal cancers. By improving the diagnostic accuracy of ultrasound imaging, use of Solstice’s unique microbubble contrast agent may enable earlier, more accurate diagnoses of RCC.
Significant Patient Benefits
The technology also promises to have wide applicability in the clinical setting beyond diagnostic imaging, including monitoring blood flows and pressures and localized drug delivery. Many investors were attracted to the diverse range of potential clinical indications for the unique microbubble technology, from patient-friendly diagnostics for young children at the bedside to revolutionary drug delivery systems for neurological diseases.
“There are many important clinical applications for which the contrast agent of Solstice has a unique added value,” said Jan Sigger, a serial-entrepreneur in the medical technology field and Founder of Quirem Medical. “I am confident that, together with the rest of the shareholders, we will realize significant patient benefits by utilizing the full potential of the Solstice microbubble technology.”
InCorpe, in Hengelo (O), and Brouwer Legal, in Enschede, advised Solstice on this financing round.
About Solstice Pharmaceuticals
Solstice Pharmaceuticals is a Dutch company dedicated to creating the next generation of diagnostic and therapeutic ultrasound products. They develop, manufacture and commercialize ultrasound contrast agents to support healthcare professionals in effectively and accurately diagnosing their patients.
www.solsticepharma.com
About Parker Laboratories
Parker Laboratories is a leading global medical products company that develops, manufactures and sells ultrasound and electromedical contact media and accessories, as well as leading lines of instrument cleaners and disinfectants. A worldwide leader in ultrasound medical products for over 60 years, Parker Laboratories has been consistently at the forefront of technological advances in the industry. Its flagship product, Aquasonic®100 Ultrasound Transmission Gel, is the world standard for medical ultrasound.
www.parkerlabs.com
About SOLSTICE PHARMACEUTICALS
Read more about Solstice Pharmaceuticals
First draft of program iMNC21 published, register now!
The program for the international MicroNanoConference 2021 is well underway with speakers from academia and industry. On December 2 and 3, 2021 we look forward to meeting you on location in Utrecht, at the Jaarbeurs.
This year’s main theme is: From science to market – scale-up in nanotech
With these sub sessions, that you will find in the program:
Tickets are now available at an early bird rate and it is now also possible to submit an abstract for either a poster or oral presentation at the conference. Read more about the program, tickets and abstract submission on the iMNC21 website.
For companies who would like to both support the micro- nano community and also showcase their company to this community, sponsor and exhibitor opportunities will be published soon.
Read more: micronanoconference.org
First edition of NanoLabNL Manifesto offered to State Secretary Keijzer
On Monday 14 June the Dutch State Secretary for Economic Affairs and Climate Policy Mona Keijzer, visited the Quantum Delta NL Center for Quantum Materials and Technology in Eindhoven. During this working visit she was shown some of the cutting edge research projects and laboratories that stand to benefit directly from the € 615 million award from the National Growth Fund.
Alongside the discussions on Quantum, there was some time to focus on the unique open infrastructure that puts The Netherlands at the forefront of innovation in quantum- and nanotechnology. Out of the € 615 million NGF award, € 150 million is reserved for maintaining and developing this infrastructure. Prof. Guus Rijnders, chairman of NanoLabNL and member of the supervisory board of Quantum Delta, explained from first-hand experience why and how NanoLabNL develops and maintains a thriving technological ecosystem.
Guus Rijnders also offered Mrs. Keijzer the first edition of the newly published NanoLabNL Manifesto; a broad testimony that focuses on the importance of open access high-tech cleanrooms, facilities and equipment, important for education, research, technology development and transfer. NanoLabNL is crucial in maintaining our leading position in many current and future science, as well as research & innovation, that rely on micro and nano fabrication. He expressed his appreciation for the financial support and urged the State Secretary to keep the subject of a healthy and viable scientific climate high on the political agenda.
Download the manifesto